Apyx Medical Corporation
US ˙ NasdaqGS ˙ US03837C1062

Introduction

This page provides a comprehensive analysis of the known insider trading history of Matthew C Hill. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Matthew C Hill has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:APYX / Apyx Medical Corporation Chief Financial Officer 8,500
US:PDSB / PDS Biotechnology Corporation Chief Financial Officer 4,075
US:SSKN / STRATA Skin Sciences, Inc. Chief Financial Officer 150,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Matthew C Hill. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APYX / Apyx Medical Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APYX / Apyx Medical Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-08-13 APYX HILL MATTHEW C 5,336 1.1300 5,336 1.1300 6,030 328 2.5800 7,738 128.34
2024-08-13 APYX HILL MATTHEW C 6,000 1.1300 6,000 1.1300 6,780
2023-12-12 APYX HILL MATTHEW C 2,500 2.1900 2,500 2.1900 5,475

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APYX / Apyx Medical Corporation Insider Trades
Insider Sales APYX / Apyx Medical Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APYX / Apyx Medical Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APYX / Apyx Medical Corporation Insider Trades
Insider Purchases EDGE / EA Series Trust - MRBL Enhanced Equity ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APYX / Apyx Medical Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-12-13 PDSB HILL MATTHEW C 2,500 9.0000 2,500 9.0000 22,500 353 9.7800 1,950 8.67
2021-12-13 PDSB HILL MATTHEW C 400 8.9000 400 8.9000 3,560
2021-12-13 PDSB HILL MATTHEW C 100 9.0000 100 9.0000 900
2021-12-13 PDSB HILL MATTHEW C 100 9.0000 100 9.0000 900

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EDGE / EA Series Trust - MRBL Enhanced Equity ETF Insider Trades
Insider Sales EDGE / EA Series Trust - MRBL Enhanced Equity ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APYX / Apyx Medical Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EDGE / EA Series Trust - MRBL Enhanced Equity ETF Insider Trades
Insider Purchases SSKN / STRATA Skin Sciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APYX / Apyx Medical Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-06-14 SSKN HILL MATTHEW C 3,646 1.9700 365 19.7000 7,183 99 37.5 6,468 90.06
2018-06-14 SSKN HILL MATTHEW C 4,542 1.9600 454 19.6000 8,902
2018-06-14 SSKN HILL MATTHEW C 1,812 1.9500 181 19.5000 3,533

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SSKN / STRATA Skin Sciences, Inc. Insider Trades
Insider Sales SSKN / STRATA Skin Sciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APYX / Apyx Medical Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SSKN / STRATA Skin Sciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Matthew C Hill as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-03 2024-08-13 4/A APYX Apyx Medical Corp
Common Stock
P - Purchase 6,000 8,500 240.00 1.13 6,780 9,605
2024-08-13 2024-08-13 4 APYX Apyx Medical Corp
Common Stock
P - Purchase 5,336 7,836 213.44 1.13 6,030 8,855
2023-12-14 2023-12-12 4 APYX Apyx Medical Corp
Common Stock
P - Purchase 2,500 2,500 2.19 5,475 5,475
2021-12-14 2021-12-13 4 PDSB PDS Biotechnology Corp
Common Stock
P - Purchase 100 4,075 2.52 9.00 900 36,675
2021-12-14 2021-12-13 4 PDSB PDS Biotechnology Corp
Common Stock
P - Purchase 100 4,075 2.52 9.00 900 36,675
2021-12-14 2021-12-13 4 PDSB PDS Biotechnology Corp
Common Stock
P - Purchase 400 3,875 11.51 8.90 3,560 34,488
2021-12-14 2021-12-13 4 PDSB PDS Biotechnology Corp
Common Stock
P - Purchase 2,500 3,475 256.41 9.00 22,500 31,275
2021-10-20 2021-10-19 4 PDSB PDS Biotechnology Corp
Stock Option (Right to Buy)
A - Award 202,800 202,800
2021-10-20 3 PDSB PDS Biotechnology Corp
Common Stock
975
2020-11-13 2020-11-13 4 SSKN STRATA Skin Sciences, Inc.
SSKN Stock Options (right to buy)
A - Award 150,000 150,000
2019-11-26 2019-11-22 4 SSKN STRATA Skin Sciences, Inc.
SSKN Stock Options (right to buy)
A - Award 150,000 400,000 60.00
2018-06-14 2018-06-14 4 SSKN STRATA Skin Sciences, Inc.
SSKN Common Stock
P - Purchase 1,812 10,000 22.13 1.95 3,533 19,500
2018-06-14 2018-06-14 4 SSKN STRATA Skin Sciences, Inc.
SSKN Common Stock
P - Purchase 4,542 8,188 124.57 1.96 8,902 16,048
2018-06-14 2018-06-14 4 SSKN STRATA Skin Sciences, Inc.
SSKN Common Stock
P - Purchase 3,646 3,646 1.97 7,183 7,183
2018-05-24 2018-05-23 4 SSKN STRATA Skin Sciences, Inc.
STRATA Stock Option (right to buy)
A - Award 250,000 250,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)